95 filings
Page 3 of 5
8-K
a7gpew0zd2lt ckt9p
25 Apr 23
Entry into a Material Definitive Agreement
5:00pm
8-K
lqo uuhb7
19 Apr 23
Allarity Therapeutics, Inc. Announces Pricing of $7.5 Million Public Offering
4:30pm
8-K
dmbephmo8 8mwuf
12 Apr 23
Entry into a Material Definitive Agreement
5:00pm
8-K
v11jjgtc9h6fbws8
11 Apr 23
Abstract Evaluating Allarity’s DRP® Companion Diagnostic for Cisplatin Accepted at 2023 ASCO Annual Meeting
9:19am
8-K
1xinh nlhsqjt
28 Mar 23
Allarity Therapeutics Provides Updates for IXEMPRA and Stenoparib Phase 2 Monotherapy Clinical Studies
5:15pm
8-K
24yxem 2g3h6wg43nh
24 Mar 23
Allarity Therapeutics Announces Reverse Stock Split of Common Stock
6:08am
8-K
og9qni34j
20 Mar 23
Amendments to Articles of Incorporation or Bylaws
5:14pm
8-K
80v soreiqe
20 Mar 23
Regulation FD Disclosure
6:05am
8-K
fmgv61kea4zgyz1
9 Mar 23
Regulation FD Disclosure
5:10pm
8-K
jwmbmbsvw48ghvv3g7
28 Feb 23
Entry into a Material Definitive Agreement
5:25pm
8-K
kvm7x a4ws
10 Feb 23
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
5:00pm
8-K
9clskgv jxo56472
6 Feb 23
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
6:33am
8-K
ioj5 qn3lv5qj9vx
23 Jan 23
Entry into a Material Definitive Agreement
6:30am
8-K
zew9nso8i6e7sqa0udl0
20 Jan 23
Allarity Therapeutics Announces Adjournment of
4:17pm
8-K
3ccve04d pb
19 Jan 23
Entry into a Material Definitive Agreement
4:01pm
8-K
z9h8k e76ukgtcvj
18 Jan 23
Other Events
6:03am
8-K
ifa8i
23 Dec 22
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
6:30am
8-K
9hbu5vm j93r0
21 Dec 22
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
9:15am
8-K
mxyv3qsxb
12 Dec 22
Entry into a Material Definitive Agreement
6:01am
8-K
jk826ljte kac
1 Dec 22
Allarity Therapeutics Reschedules 2022 Annual Stockholders Meeting
4:43pm